Zydus gets USFDA nod to market Doxycycline Capsules USP

19 Feb 2016 Evaluate

Zydus Cadila has received approval from the USFDA to market Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg. The drug falls in the anti-bacterials segment.  With this first approval, the group will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad.  The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

886.50 10.40 (1.19%)
22-Jan-2026 14:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1633.15
Dr. Reddys Lab 1217.20
Cipla 1369.70
Zydus Lifesciences 886.50
Lupin 2162.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×